SORT BY

FILTER BY

fastest growing stats

also on other fortune lists

100 Fastest-Growing Companies

Courtesy of Gilead Sciences

63

Gilead Sciences

GILD

Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.

Looking for leads, investment insights, or competitive intelligence?

Location

Foster City, Calif.

Industry

Pharmaceuticals

Sector

Health Care

Current Streak

3

Years on List

8

CEO

John Milligan

Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Revenue, Net Income
$ millions
Revenue past four quarters ($M)$29,10129,101%
Net Income past four quarters ($M)$12,63712,637%
Growth Rates and Ranks
Revenue 3 Yr Growth Rank48
Revenue 3 Yr Annual Growth Rate32%
EPS 3 Yr Growth Rank30
EPS 3 Yr Annual Growth Rate58%
Total Return 3 Yr Rank96
Total Return 3 Yr Annual Rate-4%
Beat S&P 500 (9.6%)No
P/E Ratio9
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.

Read More →
New Zealand Is About to Make the Revolutionary HIV Prevention Drug Truvada Almost Free

The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.

Read More →
The Diseases We Aren't Curing—And Why

Drug makers are flocking to certain treatment types. Why do others get left behind?

Read More →